BIG PICTURE
Biosimilars save
the US healthcare system an estimated $5.4 billion each year.*
Biocon Biologics is a proud leader in the advancement of biosimilars. As we
continue to drive innovation and invest in the
future, our mission is singularly focused on the
development, manufacturing, distribution,
and commercialization of the highest quality
biosimilars in the world.
Biocon Biologics
A fully integrated global biosimilars company, all in on biosimilars.
 20+biosimilars approved or in development
 8biosimilars launched across global markets
 100+countries where
biosimilars
are available
 5.5 Mserved globally by
Biocon Biologics'
biosimilars
* Estimates ofreductions in direct spending on biologic drugs from 2014 through 2024.
Reference: Mulcahy AW, Hlavka JP, Case SR. Biosimilar cost savings in the United States: initial experience and future potential. Rand Health Q. 2018;7(4):3. LEGACY OF SUCCESS
A long-standing presence in the biosimilars industry
Biocon Biologics has emerged as a leader in biosimilars in the US and worldwide, providing innovative and more affordable ways to treat diabetes, cancer, and autoimmune diseases. As a result of its successful global partnership with Viatris, Biocon Biologics has broadened its biosimilars capability from lab to market, commercializing the products it has been making for years.
Founded to
improve access to quality bioenzymes 
Evolves into
bio-pharmaceuticals 
First and only
company to commercialize a Pichia pastoris derived rh-insulin rh=recombinant human 
Partners with
US-based Mylan to co-develop biosimilar antibodies portfolio for global markets 
Launches world's
first trastuzumab biosimilar 
Solidifies foothold
in US and global biosimilars space 
Continues
partnership with Viatris after Mylan/Upjohn merger 
Biocon Biologics
acquires Viatris' global biosimilars business to become a fully integrated biosimilars company in the US PORTFOLIO
Path-breaking
offerings with a focus on the future.
With a unique portfolio of monoclonal antibodies and insulins, Biocon Biologics is fully committed to the long-term sustainability of global biosimilars access, investing more than $1 billion in R&D and global-scale manufacturing over the last 2 decades.
 FULPHILA® (pegfilgrastim-jmdb) injection* FIRST to receive US approval - 2018 (5+ global markets) OGIVRI® (trastuzumab-dkst) injection†‡ FIRST to receive US approval - 2017 (5+ global markets) †Please see accompanying full US Prescribing Information, including BOXED WARNING. Bevacizumab‡ Approved in EU 2021 (3+ global markets) Filed for US approval Denosumab‡ In global clinical trials Pertuzumab‡ In global clinical trials HULIO® (adalimumab-fkjp) injection†‡§¶ US approval 2020 Approved in EU 2018 (3+ global markets) †Please see accompanying full US Prescribing Information, including BOXED WARNING. Etanercept§ Approved in EU 2020 (EU market) Ustekinumab‡ In global clinical trials SEMGLEE® (insulin glargine-yfgn) injection FIRST US approval of interchangeable biosimilar - 2021 Approved in EU 2019 (6+ global markets) Glargine 300U In early development/ preclinical stage Aspart Approved in EU 2021 (2+ global markets) Filed for US approval Recombinant human insulin* Approved in 40+ global markets Filed for US approval Aflibercept# Filed for US approval In clinical trial OUS 7 assets In early development/ preclinical stage Biocon Biologics: an integrated player with proven end-to-end expertise  Research and
innovation  Product
Development  Clinical
Trials  Global-scale
Manufacturing  Regulatory
Sciences  Commercialization
Portfolio
Oncology  Immunology  Diabetes  Bone Health  Ophthalmology
Our ongoing efforts continue to expand affordable
access to biosimilars for patients worldwide
*Recombinant proteins. ‡Monoclonal antibodies. §In-licensed products. ¶Hulio will not be marketed in the US until July 2023. #Biocon Biologics has acquired the Viatris global rights to partnered asset.
EU: European Union. OUS: Outside the United States. 
Biocon Biologics Inc.
100 Somerset Corporate Boulevard, 2nd Floor, Bridgewater NJ 00807. |